Live Breaking News & Updates on Retinal Pigment Epithelium|Page 4

Stay updated with breaking news from Retinal pigment epithelium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021 Annual Virtual Meeting

Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO 2021 Annual Virtual Meeting
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.

Michaelr Robinson , Administration Of Brimonidine Drug Delivery , Drug Administration , Study Group , Association For Research , Virtual Meeting , Allergan Eye Care , New Drug Application , Gel Stent , Bimatoprost Implant , Extension Study , Candidate Drugs , Drug Delivery Rates , Bimatoprost Implant Biodegradation , Clinical Studies , Endothelial Cell Loss Associated , Selective Laser , Ocular Blood Flow , Retrospective Analysis , Visual Field Progression , Brimonidine Drug Delivery , Stent Placement , Real World Data , Vision Related Reading Ability With , Presbyopia Impacts , Coping Behaviors ,

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models

Share this article
Share this article
NEW YORK and PERTH, Australia, March 2, 2021 /PRNewswire/ PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that the Company s lead investigational drug, VP-001, for the treatment of RP11 has restored function of the Retinal Pigment Epithelium, the target cells for the therapy, in patient-derived models of the disease.
Figure 1. Structure of the retina and changes in RP-11 patients
Image created using Biorender.com
Figure 2. VP-001 treatment improves barrier function in penetrant patient iPSC-RPE Barrier function is assessed by trans-epithelial electrical resistance, T.E.E.R. (measured in Ω.cm2), with increasing Ω.cm2 representing increasing barrier function. Statistical significance calculated as one-way ANOVA = p ≤ 0.05 in cells from a single patient across two technical replicate ....

Deborah Elson Matthew Deyoung , Sahm Nasseri , Leo Vartorella , Drug Administration , Retinal Pigment Epithelium , Blood Retina Barrier , Adeno Associated Virus , Investigational New Drug , Cell Penetrating Peptides , Mol Ther Methods Clin , Matthew Deyoung , Pyc Therapeutics , டெபோரா எல்சன் மேத்யூ டியூன் , இரத்தம் விழித்திரை தடை , மோள் தெர் முறைகள் கிளினிக் , மேத்யூ டியூன் , பய்க் சிகிச்சை ,

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease

Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.

United States , Paul Michaels , Boca Raton , Financial Industry Regulatory Authority Inc , National Institutes Of Health , International Patent Application No , National Eye Institute , See Campaign , Securities Exchange , Curative Biotechnology Inc , Connectyx Technologies Holdings Group Inc , Technologies Holdings Group , Exclusive Patent License Agreement , National Institutes , Retinal Degeneration , Treat Retinal , Retinal Pigment Epithelium , Age Related Macular Degeneration , Stargardt Disease , Retinitis Pigmentosa , Connectyx Technologies Holdings Group , Curative Biotechnology , Financial Industry Regulatory Authority , Rare Disease , Securities Act , Securities Exchange Act ,